PSMA-PET Imaging Before and After ADT in Advanced SDC Patients

Salivary Gland Cancer Clinical Trial

— ADT-SCAN  

Official title:

Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma: an Explorative Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04214353
• Other study ID #: MOHN19
• Status: Recruiting
• Phase: N/A
• Start date: January 14, 2020
• Est. completion date: September 2023

Study information

• Verified date: August 2022
• Source: Radboud University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.

Description:

Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer.

This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. However, since 60% of SDC patients showed low ligand uptake, these patients are not suitable for PSMA radioligand therapy. For advanced SDC, androgen deprivation therapy is often given as first-line treatment, because the majority of SDCs are androgen receptor positive. In prostate cancer, androgen deprivation therapy (ADT) can increase PSMA-ligand uptake. Therefore the aim is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC, as has previously been demonstrated in prostate cancer.

Objective: The primary objective is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC.

Study design: Interventional clinical trial, an explorative study. Study population: Patients with locally advanced, recurrent or metastatic (R/M) SDC AR+ and who will start ADT as standard of care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14
• Est. completion date: September 2023
• Est. primary completion date: May 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have the ability to provide written informed consent.

• Patients must be = 18 years of age.

• Patients must have histological, pathological, and/or cytological confirmation of salivary duct carcinoma, androgen receptor positive.

• Only patients with locally advanced, recurrent or metastatic salivary duct carcinoma can participate.

• Patients must have at least one lesion with a diameter of = 1.5 cm.

• Patients whom intend to start androgen deprivation therapy, after this has been recommended by the treating physician as standard treatment.

Exclusion Criteria:

• Contra-indication for PET imaging (pregnancy, breast feeding severe claustrophobia)

• Impaired renal function: MDRD <30 ml/min/1,73 m2

• Impaired liver function: AST and ALT ALT = 2.5 x ULN (=5 x ULN for patients with liver metastases)

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Ductal
• Salivary Duct Carcinoma
• Salivary Gland Cancer
• Salivary Gland Neoplasms

Intervention

Diagnostic Test:
• 68Ga-PSMA-PET/CT
All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
• 18FDG-PET/CT
All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen	Gelderland

Sponsors (2)

Lead Sponsor	Collaborator
Radboud University Medical Center	Dutch Cancer Society

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of patients with a change in PSMA ligand uptake after ADT	The percentage of patients with an androgen deprivation therapy (ADT) induced change in PSMA ligand uptake on 68Ga-PSMA-PET/CT.; pre-scan: baseline (before ADT), post-scan: 3 weeks after start ADT (± 1 week).	Up to 4 weeks
Secondary	Change in 68Ga-PSMA uptake of tumor lesions	Comparison of SUV (standardized uptake value) in 68Ga-PSMA PET/CT between lesions before and 3 weeks after the initiation of ADT (± 1 week).	Up to 4 weeks
Secondary	Change in 18FDG uptake of tumor lesions	Comparison of SUV (standardized uptake value) in 18FDG-PET/CT between lesions before and 3 weeks after the initiation of ADT (± 1 week).	Up to 4 weeks
Secondary	Lesions detected by 68Ga-PSMA-PET/CT pre- and post ADT	The number of lesions detected on 68Ga-PSMA-PET/CT imaging will be measured, both before and after ADT.	Up to 4 weeks
Secondary	FDG and PSMA uptake patterns of SDC disease	FDG and PSMA uptake patterns of SDC disease on 68Ga-PSMA-PET/CT and 18FDG-PET/CT will be measured, e.g. to explore if most lesions show both FDG and PSMA uptake, or if the lesions show a more heterogenous uptake.	Up to 4 weeks
Secondary	Diagnostic added value 68Ga-PSMA-PET/CT and 18FDG-PET/CT.	The number of lesions detected by each imaging modality (diagnostic CT, 68Ga-PSMA-PET/CT and 18FDG-PET/CT) will be measured.	Up to 4 weeks
Secondary	Correlation PSMA expression and PSMA ligand uptake	The tumor uptake (SUV) will be correlated to the degree of immunohistochemical PSMA expression on the most recent tumormaterial.	Up to 6 months